Back to Journals » OncoTargets and Therapy » Volume 11

A patient with classic biphasic pulmonary blastoma harboring CD74–ROS1 fusion responds to crizotinib

Authors Meng Z, Chen P, Zang F, Liu Y, Xu X, Su Y, Chen J, Lin L, Zhang L, Zhang T

Received 25 August 2017

Accepted for publication 16 November 2017

Published 28 December 2017 Volume 2018:11 Pages 157—161


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Editor who approved publication: Dr Yao Dai

Zhaoting Meng,1,* Peng Chen,1,* Fenglin Zang,1 Ying Liu,1 Xiaoyan Xu,1 Yudong Su,1 Jinliang Chen,1 Li Lin,1 Lu Zhang,2 Tengfei Zhang2

1Department of Thoracic Medical Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 2Burning Rock Biotech, Guangzhou, China

*These authors contributed equally to this work

Abstract: Pulmonary blastoma (PB) is a rare aggressive lung malignancy with a poor prognosis. Surgical resection is the treatment of choice for localized disease, and there are no standard treatment guidelines for metastatic PB. Due to its rareness, its molecular profile has not been elucidated. We present the first case of classic biphasic pulmonary blastoma (CBPB) with CD74–ROS1 rearrangement in a 44-year-old Asian female with stage IV disease diagnosed using capture-based ultra-deep targeted sequencing. It has been reported that ROS1 rearranged lung adenocarcinoma and squamous cell carcinoma are sensitive to crizotinib, an ALK/MET/ROS1 multitargeted tyrosine kinase inhibitor. However, its efficacy has not been reported in CBPB patients harboring ROS1 rearrangement. This CBPB patient was given crizotinib and she achieved partial response after 1 month of treatment. We report the first clinical evidence of efficacy shown by crizotinib for targeting CD74–ROS1 fusion in CBPB.

Keywords: classic biphasic pulmonary blastoma, ROS1 rearrangement, crizotinib, targeted DNA sequencing

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]